Meeder Asset Management’s NovoCure NVCR Stock Holding History

Meeder Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$501K	Buy	+33,073	New	+$500K	0.03%	218
2024 Q4	–	Sell	-4,017	Closed	-$62.8K	–	985
2024 Q3	$62.8K	Sell	4,017 -704	-15%	-$12.8K	﹤0.01%	333
2024 Q2	$80.9K	Buy	+4,721	New	+$83K	0.01%	283
2021 Q4	–	Sell	-2	Closed	–	–	1952
2021 Q3	$0	Sell	2 -1,655	-100%	-$250K	﹤0.01%	2591
2021 Q2	$368K	Buy	1,657 +382	+30%	+$74.3K	0.02%	588
2021 Q1	$168K	Buy	1,275 +1,274	+127,400%	+$202K	0.01%	775
2020 Q4	$0	Hold	1	–	–	﹤0.01%	2113
2020 Q3	$0	Buy	+1	New	+$80	﹤0.01%	2311
2020 Q2	–	Sell	-320	Closed	-$22K	–	2315
2020 Q1	$22K	Sell	320 -1,126	-78%	-$89K	﹤0.01%	1207
2019 Q4	$122K	Buy	1,446 +807	+126%	+$65.1K	0.01%	737
2019 Q3	$48K	Buy	+639	New	+$51.1K	﹤0.01%	1031
2018 Q1	–	Sell	-3	Closed	–	–	1688
2017 Q4	$0	Buy	+3	New	+$58	﹤0.01%	1754
2017 Q2	–	Sell	-382	Closed	-$3K	–	1807
2017 Q1	$3K	Hold	382	–	–	﹤0.01%	1269
2016 Q4	$3K	Buy	+382	New	+$3.07K	﹤0.01%	904

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Meeder Asset Management's NVCR Position: Q2 2026 in Review

Meeder Asset Management opened a new position in NovoCure (NVCR) in Q2 2026: 33,073 shares worth $501K. The stake represents 0.03% of the portfolio and ranks #218 among its holdings. This is a return to the name: Meeder Asset Management previously reported a position in NVCR as recently as Q3 2024.

Meeder Asset Management first reported a position in NVCR in Q4 2016 and has held it in 14 quarters since. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Meeder Asset Management held 33,073 shares of NovoCure worth $501K as of Q2 2026.
NovoCure was a new Meeder Asset Management position in Q2 2026.
NovoCure made up 0.03% of Meeder Asset Management's portfolio in Q2 2026, its #218 holding.
Meeder Asset Management first reported a position in NovoCure in Q4 2016 and has held it in 14 quarters since.
218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.